Curatis Holding AG / Key word(s): Legal Matter/Strategic Company Decision
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study
31.07.2025 / 06:00 CET/CEST

MEDIA RELEASE

Liestal, Switzerland– Curatis Holding AG (SIX: CURN) – July 31, 2025. The U.S. Food and Drug Administration (FDA) have agreed to a Type B meeting in Q3 2025 to review the Phase 3 clinical development plan for corticorelin, a novel investigationalbiologic in development to treat Peritumoral Brain Edema (PTBE).

The meeting aims to achieve alignment on the design of a pivotal Phase 3 clinical trial for corticorelin, planned for initiation in 2026, as well as on key non-clinical and manufacturing aspects.

“This meeting is a critical step forward in advancing the development of corticorelin to  substantially reduce steroid-use in PTBE patients and thereby demonstrate an impact on clinically meaningful endpoints,” said Dr. Roland Rutschmann, CEO of Curatis. “We are committed to completing development and delivering this novel treatment to address a major unmet need.”

About Corticorelin (C-PTBE-01)

Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated preclinically (in vivo) the ability to positively impact the blood-brain barrier after a disruption due to the underlying malignant tumor. In two clinical studies in patients with PTBE, corticorelin, demonstrated the potential to substantially reduce, or in some cases completely replace steroid use, which may reduce or avoid the severe glucocorticoid-related side effects and subsequently improve quality of life. In the US alone, more than 150,000 patients suffer from PTBE. Corticorelin is an investigational drug not approved for therapeutic use in the United States or outside the United States.

About Curatis

Curatis Holding AG is a publicly listed company (CURN.SW) specializing in the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orphan and specialty drugs. More information can be found on the website www.curatis.com.

Contact

Patrick Ramsauer, CFO
Phone: +41 61 927 8777
ir@curatis.com

Disclaimer

The information contained in this media release and in any link to our website indicated herein is not for use within any country or jurisdiction or by any persons where such use would constitute a violation of law. If this applies to you, you are not authorized to access or use any such information.

This media release contains “forward-looking statements” that are based on our current expectations, assumptions, estimates and projections about us and our industry. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words “may”, “will”, “should”, “continue”, “believe”, “anticipate”, “expect”, “estimate”, “intend”, “project”, “plan”, “will likely continue”, “will likely result”, or words or phrases with similar meaning. Undue reliance should not be placed on such statements because, by their nature, forward-looking statements involve risks and uncertainties, including, without limitation, economic, competitive, governmental and technological factors outside of the control of Curatis Group, that may cause Curatis’ business, strategy or actual results to differ materially from the forward-looking statements (or from past results). For any factors that could cause actual results to differ materially from the forward-looking statements contained in this media release, please see the risk factors included in our listing prospectus in connection with the Business Combination. Curatis Group undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise. It should further be noted that past performance is not a guide to future performance. Persons requiring advice should consult an independent adviser.

The information contained in this media release is not an offer to sell or a solicitation of offers to purchase or subscribe for securities. This media release is not a prospectus within the meaning of the Swiss Financial Services Act nor a prospectus under any other applicable laws.

Some financial information in this media release has been rounded and, as a result, the figures shown as totals in this media release may vary slightly from the exact arithmetic aggregation of the figures that precede them.

End of Media Release